85 search results for: Pathophysiology

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

Join Prof. Kathryn Peterson for an expert review on how different immune cells and inflammatory mediators contribute to the pathogenesis of EoE.

Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

Explore the clinical presentation and pathophysiology of chronic spontaneous urticaria in this animated video. Learn about the complex mechanism of disease involving mast cell activation and the release of inflammatory mediators.

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

Join experts Dédée Murrell, Donna Aline Culton, Joost Meijer and Enno Schmidt for an educational presentation on the clinical presentation, disease burden, diagnosis, and underlying pathophysiology of bullous pemphigoid (BP). Dive deeper into unmet needs and treatment challenges faced by these patients and how targeted therapies may address them.

This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.